Cargando…

The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone

BACKGROUND: Simplistic two-dimensional (2D) in vitro assays have long been the standard for studying the metastatic abilities of cancer cells. However, tri-dimensional (3D) organotypic models provide a more complex environment, closer to that seen in patients, and thereby provide a more accurate rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritch, Sabrina J., Noman, Abu Shadat M., Goyeneche, Alicia A., Telleria, Carlos M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733158/ https://www.ncbi.nlm.nih.gov/pubmed/36494669 http://dx.doi.org/10.1186/s12935-022-02822-5

Ejemplares similares

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
por: Goyeneche, Alicia A, et al.
Publicado: (2012)

The Capacity of High-Grade Serous Ovarian Cancer Cells to Form Multicellular Structures Spontaneously along Disease Progression Correlates with Their Orthotopic Tumorigenicity in Immunosuppressed Mice
por: Goyeneche, Alicia, et al.
Publicado: (2020)

Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling
por: Ritch, Sabrina J., et al.
Publicado: (2019)

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity
por: Freeburg, Elizabeth M, et al.
Publicado: (2009)

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
por: Lisio, Michael-Antony, et al.
Publicado: (2019)

Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin
por: Kapperman, Heather E., et al.
Publicado: (2018)

Anticancer effects of mifepristone on human uveal melanoma cells
por: Alvarez, Prisca Bustamante, et al.
Publicado: (2021)

Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells
por: Abdalbari, Farah H., et al.
Publicado: (2023)

Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics
por: Brandhagen, BreeAnn N, et al.
Publicado: (2013)

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
por: Tieszen, Chelsea R, et al.
Publicado: (2011)

Synergistic Lethality of Mifepristone and LY294002 in Ovarian Cancer Cells
por: Wempe, Stacy L., et al.
Publicado: (2013)

Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition
por: Subeha, Mahbuba R., et al.
Publicado: (2021)

The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination
por: Ritch, Sabrina J., et al.
Publicado: (2022)

Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2
por: Goyeneche, Alicia A., et al.
Publicado: (2011)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial–mesenchymal cooperative interaction
por: Goyeneche, Alicia A., et al.
Publicado: (2015)

In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
por: Kim, Olga, et al.
Publicado: (2020)

Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression
por: Ponikwicka-Tyszko, Donata, et al.
Publicado: (2019)

Mifepristone Repurposing in Treatment of High-Grade Gliomas
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2021)

Exogenous estradiol enhances apoptosis in regressing post-partum rat corpora lutea possibly mediated by prolactin
por: Goyeneche, Alicia A, et al.
Publicado: (2005)

Antiprogestins in gynecological diseases
por: Goyeneche, Alicia A, et al.
Publicado: (2015)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
por: Nath, Aritro, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
por: Tone, Alicia A, et al.
Publicado: (2014)

Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma
por: Barrie, Allison M., et al.
Publicado: (2019)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells
por: Yu, Hai-Lan, et al.
Publicado: (2019)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ep3lm3li5bh2no19aifa5idl26